FTC OKs Bristol-Myers/Teva Deal On Paraplatin
The Federal Trade Commission has approved "some terms" of a proposed settlement of a patent suit filed by drug originator Bristol-Myers Squibb Co. against a unit of Israeli generic drug maker...To view the full article, register now.
Already a subscriber? Click here to view full article